Effect of N-acetylcysteine and/or deferoxamine on oxidative stress and hyperactivity in an animal model of mania

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 32, Issue 4, 2008, Pages 1064-1068

  Valvassori, Samira S ^a   Petronilho, Fabrícia C ^a   Réus, Gislaine Z ^a   Steckert, Amanda V ^a   Oliveira, Virgínia B M ^a   Boeck, Carina R ^a   Kapczinski, Flávio ^b   Dal Pizzol, Felipe ^a   Quevedo, João ^a  

^a UNIVERSIDADE DO EXTREMO SUL CATARINENSE   (Brazil)

^b Centro de Pesquisas   (Brazil)

Author keywords

Animal model; Bipolar disorder; Deferoxamine; N acetylcysteine; Oxidative stress

Indexed keywords

ACETYLCYSTEINE; AMPHETAMINE; DEFEROXAMINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DOPAMINERGIC ACTIVITY; DRUG EFFECT; HIPPOCAMPUS; HYPERACTIVITY; LOCOMOTION; MALE; MANIA; MONOTHERAPY; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; PROTEIN CARBONYLATION; RAT;

ACETYLCYSTEINE; ANIMALS; BIPOLAR DISORDER; CENTRAL NERVOUS SYSTEM STIMULANTS; DEFEROXAMINE; DEXTROAMPHETAMINE; FREE RADICAL SCAVENGERS; HYPERKINESIS; MALE; OXIDATIVE STRESS; PROTEIN CARBONYLATION; RATS; RATS, WISTAR;

EID: 42949151342     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2008.02.012     Document Type: Article

References (52)

1. Aruoma O.I., Halliewell B., Hoey B.M., and Butler J. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 6 6 (1989) 593-597
2. Asanuma M., Miyazaki I., and Ogawa N. Dopamine- or L-DOPA-induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5 3 (2003) 165-176
3. Berger B., Gaspar P., and Verney C. Dopaminergic innervation of the cerebral cortex: unexpected differences between rodents and primates. Trends Neurosci 14 1 (1991) 21-27
4. Bergson C., Mrzljak L., Smiley J.F., Pappy M., Levenson R., and Goldman-Rakic P.S. Regional, cellular, and subcellular variations in the distribution of D1 and D5 dopamine receptors in primate brain. J Neurosci 15 12 (1995) 7821-7836
5. Borisenko G.G., Kagan V.E., Hasia C.J., and Schor N.F. Interaction between 6-hydroxydopamine and transferrin: "let my iron go". Biochemistry 39 12 (2000) 3392-3400
6. Cadet J.L., Jayanthi S., and Deng X. Speed kills: cellular and molecular bases of methamphetamine-induced nerve terminal degeneration and neuronal apoptosis. FASEB J 17 13 (2003) 1775-1788
7. Coyle J.T., and Snyder S.H. Catecholamine uptake by synaptosomes in homogenates of rat brain: stereospecificity in different areas. J Pharmacol Exp Ther 170 2 (1969) 221-231
8. De Flora S., Izzotti A., D'Agostin F., and Cesarone C.F. Antioxidant activity and other mechanisms of thiols involved in chemoprevention of mutation and cancer. Am J Med 91 3C (1991) 122S-130S
9. Ferris R.M., Tang F.L., and Maxwell R.A. A comparison of the capacities of isomers of amphetamine, deoxypipradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J Pharmacol Exp Ther 181 3 (1972) 407-416
10. Frey B.N., Andreazza A.C., Cereser K.M., Martins M.R., Valvassori S., Réus G.Z., et al. Effects of mood stabilizers on hippocampus BDNF levels in an animal model of mania. Life Sci 79 3 (2006) 281-286
11. Frey B.N., Martins M.R., Petronilho F.C., Dal-Pizzol F., Quevedo J., and Kapczinski F. Increased oxidative stress after repeated amphetamine exposure: possible relevance as a model of mania. Bipolar Disord 8 3 (2006) 275-280
12. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31 5 (2006) 326-332
13. Frey B.N., Valvassori S.S., Réus G.Z., Martins M.R., Petronilho F.C., Bardini K., et al. Changes in antioxidant defense enzymes after d-amphetamine exposure: implications as an animal model of mania. Neurochem Res 31 5 (2006) 699-703
14. Frey B.N., Andreazza A.C., Nery F.G., Martins M.R., Quevedo J., Soares J.C., et al. The role of hippocampus in the pathophysiology of bipolar disorder. Behav Pharmacol 18 5-6 (2007) 419-430
15. Froissard P., Monrocq H., and Duval D. Role of glutathione metabolism in the glutamate-induced programmed cell death of neuronal-like PC12 cells. Eur J Pharmacol 326 1 (1997) 93-99
16. Fukami G., Hashimoto K., Koike K., Okama N., Shimizu E., and Iyo M. Effect of antioxidant N-acetyl-l-cysteine on behavioral changes and neurotoxicity in rats after administration of methamphetamine. Brain Res 1016 1 (2004) 90-95
17. Gould T.J., Keith R.A., and Bhat R.V. Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav Brain Res 118 1 (2001) 95-105
18. Halliwell B. Oxidants and human disease: some new concepts. FASEB J 1 5 (1987) 358-364
19. Halliwell B. Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action?. Free Radic Biol Med 7 6 (1989) 645-651
20. Harris J.E., and Baldessarini R.J. Uptake of (3H)-catecholamines by homogenates of rat corpus striatum and cerebral cortex: effects of amphetamine analogues. Neuropharmacology 12 7 (1973) 669-679
21. Heikkila R.E., Orlansky H., Mytilineou C., and Cohen G. Amphetamine: evaluation of d- and l-isomers as releasing agents and uptake inhibitors for 3H-dopamine and 3H-norepinephrine in slices of rat neostriatum and cerebral cortex. J Pharmacol Exp Ther 194 1 (1975) 47-56
22. Holmes J.C., and Rutledge C.O. Effects of the d- and l-isomers of amphetamine on uptake, release and catabolism of norepinephrine, dopamine and 5-hydroxytryptamine in several regions of rat brain. Biochem Pharmacol 25 4 (1976) 447-451
23. Jay T.M. Dopamine: a potential substrate for synaptic plasticity and memory mechanisms. Prog Neurobiol 69 6 (2003) 375-390
24. Jiang H., Luan Z., Wang J., and Xie J. Neuroprotective effects of iron chelator Desferal on dopaminergic neurons in the substantia nigra of rats with iron-overload. Neurochem Int 49 6 (2006) 605-609
25. Kaladjian A., Mazzola-Pomietto P., Jeanningros R., and Azorin J.M. Brain structural abnormalities of bipolar disorder. Encephale 32 4 Pt 1 (2006) 421-436
26. Kopin I.J. The pharmacology of Parkinson's disease therapy: an update. Annu Rev Pharmacol Toxicol 33 (1993) 467-495
27. Kuloglu M., Ustundag B., Atmaca M., Canatan H., Tezcan A.E., and Cinkilink N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20 2 (2002) 171-175
28. LaVoie M.J., and Hastings T.G. Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine. J Neurosci 19 4 (1999) 1484-1491
29. Levine R.L., Garland D., and Oliver C.N. Determination of carbonyl content in oxidatively modified proteins. Methods Enzymol 186 (1990) 464-478
30. Lowry O.H., Rosebrough A.L., and Randal R.J. Protein measurement with the folin phenol reagent. J Biol Chem 193 1 (1951) 265-275
31. Machado-Vieira R., Kapczinski F., and Soares J.C. Perspective for the development of animals models of bipolar disorders. Prog NeuroPsycopharmacol Biol Psychiatry 28 2 (2004) 209-224
32. Martinez D., Slifstein M., Broft A., Mawlawi O., Hwang D.R., Huang Y., et al. Imaging human mesolimbic dopamine transmission with positron emission tomography. Part II. Amphetamine-induced dopamine release in the functional subdivisions of the striatum. J Cereb Blood Flow Metab 23 3 (2003) 285-300
33. Mu D., Chang Y.S., Vexler Z.S., and Ferriero D.M. Hypoxia-inducible factor 1 alpha and erythropoietin upregulation with deferoxamine salvage after neonatal stroke. Exp Neurol 195 2 (2005) 407-415
34. Olanow C.W. An introduction to the free radical hypothesis in Parkinson's disease. Ann Neurol 32 (1992) S2-S9 [Suppl]
35. Otmakhova N.A., and Lisman J.E. D1/D5 dopamine receptor activation increases the magnitude of early long-term potentiation at CA1 hippocampal synapses. J Neurosci 16 23 (1996) 7478-7486
36. Park M.J., Lee S.K., Lima M.A., Chung H.S., Cho S.I., Jang C.G., et al. Effect of alpha-tocopherol and deferoxamine on methamphetamine-induced neurotoxicity. Brain Res 1109 1 (2006) 176-182
37. Post R.M., and Weiss S.R. A speculative model of affective illness cyclicity based on patterns of drug tolerance observed in amygdale kindled seizures. Mol Neurobiol 13 1 (1996) 33-60
38. Prass K., Ruscher K., Karsch M., Isaev N., Magow D., Priller J., et al. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J Cereb Blood Flow Metab 22 5 (2002) 520-525
39. Reed D.J., and Farriss M.W. Glutathione depletion and susceptibility. Pharmacol Rev 36 2 Suppl (1984) 25S-33S
40. Ricaurte G.A., and McCann U.D. Neurotoxic amphetamine analogues: effects in monkeys and implications for humans. Ann N Y Acad Sci 648 (1992) 371-382
41. Ricaurte G.A., Seiden L.S., and Schuster C.R. Increased dopamine metabolism in rat neostriatum after toxic doses of d-methylamphetamine. Neuropharmacology 22 12A (1983) 1383-1388
42. Ritter C., Andrades M.E., Reinke A., Menna-Barreto S., Moreira J.C., and Dal-Pizzol F. Treatment with N-acetylcysteine plus deferoxamine protects rats against oxidative stress and improves survival in sepsis. Crit Care Med 32 2 (2004) 342-349
43. Ritter C., Reinke A., andrades M., Martins M.R., Rocha J., Menna-Barreto S., et al. Protective effect of N-acetylcysteine and deferoxamine on carbon tetrachloride-induced acute hepatic failure in rats. Crit Care Med 32 10 (2004) 2079-2083
44. Ritter C., da Cunha A.A., Echer I.C., Andrades M., Reinke A., Lucchiari N., et al. Effects of N-acetylcysteine plus deferoxamine in lipopolysaccharide-induced acute lung injury in the rat. Crit Care Med 34 2 (2006) 471-477
45. Robinson T.E., and Kolb B. Persistent structural modifications in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J Neurosci 17 21 (1997) 8491-8497
46. Sagrista M.L., Garcia A.F., Madariaga M.A., and Mora M. Antioxidant and pro-oxidant effect of the thiolic compounds N-acetyl-l-cysteine and glutathione against free radical-induced lipid peroxidation. Free Radic Res 36 3 (2002) 329-340
47. Shaldivin A., Kaptsan A., Belmaker R.H., Einat H., and Grisaru N. Transcranial magnetic stimulation in an amphetamine hyperactivity model of mania. Bipolar Disord 3 1 (2001) 30-34
48. Solov'eva M.E., Solov'ev V.V., Faskhutdinova A.A., Kudriavtsev A.A., and Akatov V.S. Prooxidant and cytotoxic action of N-acetylcysteine and glutathione combined with vitamin Bl2b. Tsitologiia 49 1 (2007) 70-78
49. Stokes A.H., Hastings T.G., and Vrana K.E. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 55 6 (1999) 559-565
50. Vianna M.R., Izquierdo L.A., Barros D.M., de Souza M.M., Rodrigues C., Sant'Anna M.K., et al. Pharmacological differences between memory consolidation of habituation to an open field and inhibitory avoidance learning. Braz J Med Biol Res 34 2 (2001) 233-240
51. Wan F.J., Tung C.S., Shiah I.S., and Lin H.C. Effects of alpha-phenyl-N-tert-butyl nitrone and N-acetylcysteine on hydroxyl radical formation and dopamine depletion in the rat striatum produced by d-amphetamine. Eur Neuropsychopharmacol 16 2 (2006) 147-153
52. Yamamoto B.K., and Zhu W. The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther 287 1 (1998) 107-114